US 12,343,346 B2
Salts and solid forms of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same
Benjamin M. Cohen, Cranford, NJ (US); John F. Traverse, Lebanon, NJ (US); Jean Xu, Warren, NJ (US); and Ying Li, Millburn, NJ (US)
Assigned to Celgene Corporation, Summit, NJ (US)
Filed by Celgene Corporation, Summit, NJ (US)
Filed on Jul. 3, 2024, as Appl. No. 18/763,262.
Application 18/763,262 is a continuation of application No. 17/570,299, filed on Jan. 6, 2022, abandoned.
Application 17/570,299 is a continuation of application No. 16/800,979, filed on Feb. 25, 2020, granted, now 11,241,439, issued on Feb. 8, 2022.
Application 16/800,979 is a continuation of application No. 16/443,161, filed on Jun. 17, 2019, granted, now 10,596,180, issued on Mar. 24, 2020.
Application 16/443,161 is a continuation of application No. 15/856,845, filed on Dec. 28, 2017, granted, now 10,463,672, issued on Nov. 5, 2019.
Application 15/856,845 is a continuation of application No. 15/445,070, filed on Feb. 28, 2017, granted, now 9,884,062, issued on Feb. 6, 2018.
Application 15/445,070 is a continuation of application No. 14/945,147, filed on Nov. 18, 2015, granted, now 9,629,849, issued on Apr. 25, 2017.
Application 14/945,147 is a continuation of application No. 13/962,745, filed on Aug. 8, 2013, granted, now 9,221,788, issued on Dec. 29, 2015.
Claims priority of provisional application 61/681,484, filed on Aug. 9, 2012.
Prior Publication US 2024/0350509 A1, Oct. 24, 2024
Int. Cl. A61K 31/5377 (2006.01); A61K 31/4035 (2006.01); A61K 31/4412 (2006.01); C07D 401/04 (2006.01); C07D 401/14 (2006.01); C07D 413/14 (2006.01)
CPC A61K 31/5377 (2013.01) [C07D 401/04 (2013.01); A61K 31/4035 (2013.01); A61K 31/4412 (2013.01)] 7 Claims
 
1. A process for preparing Form F of HCl salt of Compound (I-S):

OG Complex Work Unit Chemistry
comprising slurrying Form E of HCl salt of Compound (I-S) in a solvent, wherein the solvent is a mixture of 2-propanol and water, wherein Form F of HCl salt of Compound (I-S) is characterized by an XRPD pattern comprising peaks at approximately 13.71, 14.22, and 20.87 degrees 2θ, and wherein Form E of HCl salt of Compound (I-S) is characterized by an XRPD pattern comprising peaks at approximately 9.82, 17.06, and 17.73 degrees 2θ.